Thiazolidinedione Monotherapy for T2DM Tied to Lower Dementia Risk

WEDNESDAY, Oct. 12, 2022 -- For patients with type 2 diabetes (T2D), thiazolidinedione (TZD) monotherapy is associated with reduced dementia risk compared with metformin (MET) monotherapy, while sulfonylurea (SU) monotherapy is associated with an...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news